^
    1d
    Predictive value of LncRNA LINC00667 in the development and prognosis of papillary thyroid carcinoma and its possible regulation of cellular processes via miR-34c-5p. (PubMed, Arch Biochem Biophys)
    Up-regulated LINC00667 may serve as a biomarker for PTC. Knockdown of LINC00667 may inhibit the progression of PTC by regulating miR-34c-5p.
    Journal
    |
    LINC00667 (Long Intergenic Non-Protein Coding RNA 667)
    1d
    Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC (clinicaltrials.gov)
    P=N/A, N=876, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Targeting S1PR1 in Thyroid Cancer: Functional Characterization and Proteasome-Mediated Suppression by Quercetin. (PubMed, Mol Carcinog)
    Overall, our results indicated that S1PR1 expression at the protein level has a positive relationship with thyroid cancer progression, as seen in other cancers. These data also suggest that quercetin is a potential anticancer drug that can target S1PR1-positive cells.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    2d
    Developing a prognostic stratification model based on glutathione metabolism in thyroid cancer and validating RRM2's tumor-promoting role. (PubMed, Front Oncol)
    RRM2 is a tumor-promoting gene that correlates with aggressive clinicopathologic features and functionally drives thyroid tumor growth in vitro and in vivo. These data support further investigation of GSH metabolism and RRM2 as prognostic biomarkers and potential therapeutic targets in thyroid cancer.
    Journal
    |
    CD4 (CD4 Molecule) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
    2d
    Construction and validation of risk models of prognostic genes associated with parthanatos in papillary thyroid carcinoma based on bioinformatics. (PubMed, Discov Oncol)
    This study comprehensively mapped PRGs in PTC, established a validated risk model, and provided insights into immune-microenvironment interactions and therapeutic targets, advancing precision oncology for PTC.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • CLU (Clusterin) • AKAP12 (A-Kinase Anchoring Protein 12)
    2d
    UBE2T promotes papillary thyroid carcinoma progression by activating the JAK/STAT3 pathway via negative regulation of SOCS2. (PubMed, Semin Oncol)
    Rescue experiments and immunofluorescence confirmed UBE2T promotes oncogenesis by destabilizing SOCS2, thereby relieving its inhibition of STAT3 phosphorylation. These findings establish UBE2T as a novel regulator of PTC progression through SOCS2/JAK-STAT3 axis manipulation, providing potential therapeutic targets to mitigate metastasis and recurrence in aggressive thyroid carcinomas.
    Journal
    |
    SOCS2 (Suppressor Of Cytokine Signaling 2)
    3d
    BRAF V600E-mutant squamous cell carcinoma of the lung in patients with a history of papillary thyroid carcinoma: A three-case series. (PubMed, Respir Investig)
    BRAF inhibitors yielded only transient responses, and outcomes were poor. These cases underscore the diagnostic and therapeutic value of multigene testing in SCC, highlighting the need to integrate detailed clinical history into precision oncology strategies.
    Journal
    |
    BRAF (B-raf proto-oncogene) • NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8)
    |
    BRAF V600E • BRAF V600
    3d
    Single-cell RNA-seq combined with bulk RNA-seq explores shared gene signatures between thyroid and breast cancers. (PubMed, Front Genet)
    Results from RT-qPCR and immunohistochemistry in clinical samples showed that the expression levels of PILRA, Mki67, and UBE2C were markedly different between cancerous and adjacent tissues. PILRA, MKI67, and UBE2C, as potential diagnostic and prognostic biomarkers, are anticipated to serve as promising therapeutic targets for the clinical management of both breast cancer and thyroid cancer.
    Journal • Gene Signature
    |
    PILRA (Paired Immunoglobin Like Type 2 Receptor Alpha) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    3d
    Enhancer-mediated NR2F2 recruitment activates BGN to promote tumor growth and shape tumor microenvironment in papillary thyroid cancer. (PubMed, Theranostics)
    Our findings highlight the NR2F2-BGN axis as a critical regulator of PTC progression. Targeting this axis offers a promising therapeutic strategy for PTC treatment and immune microenvironment modulation.
    Journal
    |
    BGN (Biglycan)
    3d
    The roles of both the endogenous synthesis and exogenous uptake of fatty acids in thyroid cancer cell proliferation. (PubMed, Eur J Med Res)
    Both the de novo synthesis and exogenous uptake of FAs are important for PTC cell proliferation. The combined inhibition of LPL and FASN inhibitors shows promise for PTC treatment.
    Journal
    |
    LPL (Lipoprotein Lipase)
    3d
    Papillary thyroid carcinoma: morphological features and association with normalized BRAFV600E allelic frequency; clonality and morphology investigating mutations through microscopy. (PubMed, Thyroid Res)
    The presence of infiltrative tumor margin, plump pink cells, and myxoid desmoplasia, may serve as active markers associated with the normalized BRAF V600E mutation. These findings suggest that the mutation acts as a driver in both early and late stages of PTC development. Furthermore, a direct relationship between tumor size and clonality underscores the role of BRAF V600E mutation in tumor progression and morphological evolution.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    3d
    Mortality Benefit of Ultrasound for Incidental Thyroid Nodules Identified With PET Imaging: A Non-Inferiority Emulated Target Trial (clinicaltrials.gov)
    P=N/A, N=5000, Active, not recruiting, Brigham and Women's Hospital
    New trial • Head-to-Head